A Phase Ib Study of AZD9291 (Osimertinib) and BC2059 (Tegavivint) as First-Line Therapy in Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
This study is testing a combination of two cancer medications, osimertinib and tegavivint, as a first-line treatment for a specific type of advanced lung cancer. Researchers want to find the safest and most effective doses to help stop tumor growth.
You may be able to join if you are 18 or older, have non-small cell lung cancer that has spread, and your tumor has specific EGFR genetic mutations. You also must not have received prior treatment with certain targeted cancer pills.
Participants will take the study medications and undergo regular health checks, including imaging scans like X-rays, heart function tests, and occasional tissue or fluid samples. The medical team will closely monitor you for any side effects.
This study is currently recruiting participants and takes place in Columbus, Ohio, in the United States.
- 1Tests a combination of two targeted cancer medications.
- 2Designed for adults with specific EGFR-mutant lung cancer.
- 3Involves regular check-ups, scans, and safety monitoring.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.